Rhumbline Advisers Sells 5,510 Shares of Hologic, Inc. (NASDAQ:HOLX)

Rhumbline Advisers decreased its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 509,526 shares of the medical equipment provider's stock after selling 5,510 shares during the quarter. Rhumbline Advisers owned 0.23% of Hologic worth $36,732,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Benson Investment Management Company Inc. acquired a new position in shares of Hologic in the 4th quarter valued at approximately $4,832,000. Clean Yield Group increased its holdings in Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Versor Investments LP acquired a new position in Hologic during the 3rd quarter worth approximately $1,677,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock worth $110,700,000 after acquiring an additional 238,222 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.88% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on HOLX. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Price Performance

Shares of NASDAQ HOLX traded up $0.15 during mid-day trading on Friday, hitting $64.47. 2,212,653 shares of the stock traded hands, compared to its average volume of 2,473,190. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The firm has a 50 day simple moving average of $70.09 and a two-hundred day simple moving average of $76.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market cap of $14.47 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 2.13 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.